Metformin and thyroid disease
An intriguing area of research in thyroidology is the recently discovered association of insulin resistance with thyroid functional and morphological abnormalities. Individuals with hyperinsulinemia have larger thyroid gland and a higher prevalence of thyroid nodules and cancer. Accordingly, patient...
Gespeichert in:
| Veröffentlicht in: | Journal of endocrinology 2017-04, Vol.233 (1), p.R43-R51 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | R51 |
|---|---|
| container_issue | 1 |
| container_start_page | R43 |
| container_title | Journal of endocrinology |
| container_volume | 233 |
| creator | Meng, Xianghui Xu, Shuhang Chen, Guofang Derwahl, Michael Liu, Chao |
| description | An intriguing area of research in thyroidology is the recently discovered association of insulin resistance with thyroid functional and morphological abnormalities. Individuals with hyperinsulinemia have larger thyroid gland and a higher prevalence of thyroid nodules and cancer. Accordingly, patients treated with metformin have a smaller thyroid volume and a lower risk of incident goiter, thyroid nodule and cancer. Multiple studies in vitro and in vivo have demonstrated that metformin can inhibit the growth of thyroid cells and different types of thyroid cancer cells by affecting the insulin/IGF1 and mTOR pathways. Besides, metformin treatment was associated with a decrease in the levels of serum thyroid-stimulating hormone (TSH) in diabetic patients possibly by enhancing the effects of thyroid hormones in the pituitary and activating the adenosine monophosphate-activated protein kinase (AMPK). Based on this evidence, metformin appears to be a promising therapeutic tool in patients with thyroid disease. More clinical studies are necessary to evaluate the clinical significance of metformin for the treatment of thyroid diseases. |
| doi_str_mv | 10.1530/JOE-16-0450 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1881755565</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1868698766</sourcerecordid><originalsourceid>FETCH-LOGICAL-b495t-ebd6eceb50b92b0c01417dc0e3f3d4290768fcdc8a8eaa2e3d31fb27bf50fd383</originalsourceid><addsrcrecordid>eNqN0DlLBEEQhuFGFF2PyFhZMBFktGp6-gpF1gvFROOmT2zZndHumWD_vbOsGhiIUSUPH9RLyCHCOTIKF_dPswp5BQ2DDTLBRqiKS2CbZAJQ1xUIxXbIbilvAMhQ0G2yU0tUXLFmQo4eQx-7vEjt1LR-2r8uc5f81KcSTAn7ZCuaeQkHX3ePvFzPnq9uq4enm7ury4fKNor1VbCeBxcsA6tqCw6wQeEdBBqpb2oFgsvovJNGBmPqQD3FaGthI4PoqaR75HS9-567jyGUXi9ScWE-N23ohqJRShSMMc7-QbnkSgrOR3ryi751Q27HRzQq2VDRIFsNnq2Vy10pOUT9ntPC5KVG0KvAegysketV4FEff20OdhH8j_0uOgJcA5u64lJo-xSTM3-OfgJ_H4Ox</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1984374155</pqid></control><display><type>article</type><title>Metformin and thyroid disease</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Meng, Xianghui ; Xu, Shuhang ; Chen, Guofang ; Derwahl, Michael ; Liu, Chao</creator><creatorcontrib>Meng, Xianghui ; Xu, Shuhang ; Chen, Guofang ; Derwahl, Michael ; Liu, Chao</creatorcontrib><description>An intriguing area of research in thyroidology is the recently discovered association of insulin resistance with thyroid functional and morphological abnormalities. Individuals with hyperinsulinemia have larger thyroid gland and a higher prevalence of thyroid nodules and cancer. Accordingly, patients treated with metformin have a smaller thyroid volume and a lower risk of incident goiter, thyroid nodule and cancer. Multiple studies in vitro and in vivo have demonstrated that metformin can inhibit the growth of thyroid cells and different types of thyroid cancer cells by affecting the insulin/IGF1 and mTOR pathways. Besides, metformin treatment was associated with a decrease in the levels of serum thyroid-stimulating hormone (TSH) in diabetic patients possibly by enhancing the effects of thyroid hormones in the pituitary and activating the adenosine monophosphate-activated protein kinase (AMPK). Based on this evidence, metformin appears to be a promising therapeutic tool in patients with thyroid disease. More clinical studies are necessary to evaluate the clinical significance of metformin for the treatment of thyroid diseases.</description><identifier>ISSN: 0022-0795</identifier><identifier>EISSN: 1479-6805</identifier><identifier>DOI: 10.1530/JOE-16-0450</identifier><identifier>PMID: 28196954</identifier><language>eng</language><publisher>England: Bioscientifica Ltd</publisher><subject>Adenosine kinase ; AMP ; Antidiabetics ; Cancer ; Diabetes mellitus ; Goiter ; Humans ; Hyperinsulinemia ; Hypoglycemic Agents - pharmacology ; Hypoglycemic Agents - therapeutic use ; Insulin ; Insulin-like growth factor I ; Kinases ; Metformin ; Metformin - pharmacology ; Metformin - therapeutic use ; Nodules ; Pituitary ; Pituitary Gland - drug effects ; Pituitary Gland - metabolism ; Protein kinase ; Review ; Thyroid cancer ; Thyroid diseases ; Thyroid Diseases - drug therapy ; Thyroid Diseases - metabolism ; Thyroid hormones ; Thyroid Hormones - metabolism ; Thyroid-stimulating hormone ; Thyrotropin - blood ; TOR protein</subject><ispartof>Journal of endocrinology, 2017-04, Vol.233 (1), p.R43-R51</ispartof><rights>2017 Society for Endocrinology</rights><rights>2017 Society for Endocrinology.</rights><rights>Copyright Portland Press Ltd The Biochemical Society Apr 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b495t-ebd6eceb50b92b0c01417dc0e3f3d4290768fcdc8a8eaa2e3d31fb27bf50fd383</citedby><cites>FETCH-LOGICAL-b495t-ebd6eceb50b92b0c01417dc0e3f3d4290768fcdc8a8eaa2e3d31fb27bf50fd383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28196954$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Meng, Xianghui</creatorcontrib><creatorcontrib>Xu, Shuhang</creatorcontrib><creatorcontrib>Chen, Guofang</creatorcontrib><creatorcontrib>Derwahl, Michael</creatorcontrib><creatorcontrib>Liu, Chao</creatorcontrib><title>Metformin and thyroid disease</title><title>Journal of endocrinology</title><addtitle>J Endocrinol</addtitle><description>An intriguing area of research in thyroidology is the recently discovered association of insulin resistance with thyroid functional and morphological abnormalities. Individuals with hyperinsulinemia have larger thyroid gland and a higher prevalence of thyroid nodules and cancer. Accordingly, patients treated with metformin have a smaller thyroid volume and a lower risk of incident goiter, thyroid nodule and cancer. Multiple studies in vitro and in vivo have demonstrated that metformin can inhibit the growth of thyroid cells and different types of thyroid cancer cells by affecting the insulin/IGF1 and mTOR pathways. Besides, metformin treatment was associated with a decrease in the levels of serum thyroid-stimulating hormone (TSH) in diabetic patients possibly by enhancing the effects of thyroid hormones in the pituitary and activating the adenosine monophosphate-activated protein kinase (AMPK). Based on this evidence, metformin appears to be a promising therapeutic tool in patients with thyroid disease. More clinical studies are necessary to evaluate the clinical significance of metformin for the treatment of thyroid diseases.</description><subject>Adenosine kinase</subject><subject>AMP</subject><subject>Antidiabetics</subject><subject>Cancer</subject><subject>Diabetes mellitus</subject><subject>Goiter</subject><subject>Humans</subject><subject>Hyperinsulinemia</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin</subject><subject>Insulin-like growth factor I</subject><subject>Kinases</subject><subject>Metformin</subject><subject>Metformin - pharmacology</subject><subject>Metformin - therapeutic use</subject><subject>Nodules</subject><subject>Pituitary</subject><subject>Pituitary Gland - drug effects</subject><subject>Pituitary Gland - metabolism</subject><subject>Protein kinase</subject><subject>Review</subject><subject>Thyroid cancer</subject><subject>Thyroid diseases</subject><subject>Thyroid Diseases - drug therapy</subject><subject>Thyroid Diseases - metabolism</subject><subject>Thyroid hormones</subject><subject>Thyroid Hormones - metabolism</subject><subject>Thyroid-stimulating hormone</subject><subject>Thyrotropin - blood</subject><subject>TOR protein</subject><issn>0022-0795</issn><issn>1479-6805</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0DlLBEEQhuFGFF2PyFhZMBFktGp6-gpF1gvFROOmT2zZndHumWD_vbOsGhiIUSUPH9RLyCHCOTIKF_dPswp5BQ2DDTLBRqiKS2CbZAJQ1xUIxXbIbilvAMhQ0G2yU0tUXLFmQo4eQx-7vEjt1LR-2r8uc5f81KcSTAn7ZCuaeQkHX3ePvFzPnq9uq4enm7ury4fKNor1VbCeBxcsA6tqCw6wQeEdBBqpb2oFgsvovJNGBmPqQD3FaGthI4PoqaR75HS9-567jyGUXi9ScWE-N23ohqJRShSMMc7-QbnkSgrOR3ryi751Q27HRzQq2VDRIFsNnq2Vy10pOUT9ntPC5KVG0KvAegysketV4FEff20OdhH8j_0uOgJcA5u64lJo-xSTM3-OfgJ_H4Ox</recordid><startdate>201704</startdate><enddate>201704</enddate><creator>Meng, Xianghui</creator><creator>Xu, Shuhang</creator><creator>Chen, Guofang</creator><creator>Derwahl, Michael</creator><creator>Liu, Chao</creator><general>Bioscientifica Ltd</general><general>Portland Press Ltd The Biochemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>201704</creationdate><title>Metformin and thyroid disease</title><author>Meng, Xianghui ; Xu, Shuhang ; Chen, Guofang ; Derwahl, Michael ; Liu, Chao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b495t-ebd6eceb50b92b0c01417dc0e3f3d4290768fcdc8a8eaa2e3d31fb27bf50fd383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adenosine kinase</topic><topic>AMP</topic><topic>Antidiabetics</topic><topic>Cancer</topic><topic>Diabetes mellitus</topic><topic>Goiter</topic><topic>Humans</topic><topic>Hyperinsulinemia</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin</topic><topic>Insulin-like growth factor I</topic><topic>Kinases</topic><topic>Metformin</topic><topic>Metformin - pharmacology</topic><topic>Metformin - therapeutic use</topic><topic>Nodules</topic><topic>Pituitary</topic><topic>Pituitary Gland - drug effects</topic><topic>Pituitary Gland - metabolism</topic><topic>Protein kinase</topic><topic>Review</topic><topic>Thyroid cancer</topic><topic>Thyroid diseases</topic><topic>Thyroid Diseases - drug therapy</topic><topic>Thyroid Diseases - metabolism</topic><topic>Thyroid hormones</topic><topic>Thyroid Hormones - metabolism</topic><topic>Thyroid-stimulating hormone</topic><topic>Thyrotropin - blood</topic><topic>TOR protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meng, Xianghui</creatorcontrib><creatorcontrib>Xu, Shuhang</creatorcontrib><creatorcontrib>Chen, Guofang</creatorcontrib><creatorcontrib>Derwahl, Michael</creatorcontrib><creatorcontrib>Liu, Chao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meng, Xianghui</au><au>Xu, Shuhang</au><au>Chen, Guofang</au><au>Derwahl, Michael</au><au>Liu, Chao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metformin and thyroid disease</atitle><jtitle>Journal of endocrinology</jtitle><addtitle>J Endocrinol</addtitle><date>2017-04</date><risdate>2017</risdate><volume>233</volume><issue>1</issue><spage>R43</spage><epage>R51</epage><pages>R43-R51</pages><issn>0022-0795</issn><eissn>1479-6805</eissn><abstract>An intriguing area of research in thyroidology is the recently discovered association of insulin resistance with thyroid functional and morphological abnormalities. Individuals with hyperinsulinemia have larger thyroid gland and a higher prevalence of thyroid nodules and cancer. Accordingly, patients treated with metformin have a smaller thyroid volume and a lower risk of incident goiter, thyroid nodule and cancer. Multiple studies in vitro and in vivo have demonstrated that metformin can inhibit the growth of thyroid cells and different types of thyroid cancer cells by affecting the insulin/IGF1 and mTOR pathways. Besides, metformin treatment was associated with a decrease in the levels of serum thyroid-stimulating hormone (TSH) in diabetic patients possibly by enhancing the effects of thyroid hormones in the pituitary and activating the adenosine monophosphate-activated protein kinase (AMPK). Based on this evidence, metformin appears to be a promising therapeutic tool in patients with thyroid disease. More clinical studies are necessary to evaluate the clinical significance of metformin for the treatment of thyroid diseases.</abstract><cop>England</cop><pub>Bioscientifica Ltd</pub><pmid>28196954</pmid><doi>10.1530/JOE-16-0450</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-0795 |
| ispartof | Journal of endocrinology, 2017-04, Vol.233 (1), p.R43-R51 |
| issn | 0022-0795 1479-6805 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1881755565 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adenosine kinase AMP Antidiabetics Cancer Diabetes mellitus Goiter Humans Hyperinsulinemia Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Insulin Insulin-like growth factor I Kinases Metformin Metformin - pharmacology Metformin - therapeutic use Nodules Pituitary Pituitary Gland - drug effects Pituitary Gland - metabolism Protein kinase Review Thyroid cancer Thyroid diseases Thyroid Diseases - drug therapy Thyroid Diseases - metabolism Thyroid hormones Thyroid Hormones - metabolism Thyroid-stimulating hormone Thyrotropin - blood TOR protein |
| title | Metformin and thyroid disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T11%3A50%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metformin%20and%20thyroid%20disease&rft.jtitle=Journal%20of%20endocrinology&rft.au=Meng,%20Xianghui&rft.date=2017-04&rft.volume=233&rft.issue=1&rft.spage=R43&rft.epage=R51&rft.pages=R43-R51&rft.issn=0022-0795&rft.eissn=1479-6805&rft_id=info:doi/10.1530/JOE-16-0450&rft_dat=%3Cproquest_cross%3E1868698766%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1984374155&rft_id=info:pmid/28196954&rfr_iscdi=true |